August 13, 2020
MSCopilot® development was selected for innovation support under the Innov'up Leader PIA program, jointly funded by the State and the Ile-de-France Regional Council and operated by Bpifrance.
This program will enable Ad Scientiam to continue accelerating MSCopilot® development, a CE-marked software medical device for real-world self-assessment by Multiple Sclerosis (MS) patients.
Ad Scientiam was selected by a jury of French and German experts for the French Healthcare Booster Germany program, aimed at developing our activities in Germany.
March 9, 2023
Ad Scientiam was selected by the Ile-de-France Regional Council under the PM'up program, as part of the #Leader strategy for innovation.
April 1, 2021
We announce the enrollment of the First Patient In in the HARMONY 360 study, conducted in collaboration with Merck KGaA, Darmstadt, Germany, to explore multimodal remote digital monitoring of generalized Myasthenia Gravis with MyoSense 360.
October 8, 2026
Talk to our experts and discover how our solutions integrate into your practice or studies.
This site uses analytics cookies
We use Countly to measure audience and improve your experience. This data remains anonymous and is not shared with third parties.